Laura Lorenzetti

Stay informed with Laura Lorenzetti’s coverage and analysis for Fortune.

Page 22 of 73

  • The New York Times 2015 DealBook ConferenceArts & Entertainment

    Don’t Expect Live Sports on Netflix Anytime Soon

    By
  • Masterpieces From The Taubman Collection At Sotheby'sLuxury

    A $500 Million Art Auction Kicks Off Today at Sotheby’s

    By
  • Views of The Facebook Inc. Logo Ahead of EarningsTech

    VW’s New Horror And Facebook 3Q–5 Things To Know Today

    By Laura Lorenzetti and Geoffrey Smith
  • King Raises $500 Million in "Candy Crush" Maker's U.S. OfferingTech

    Activision’s candy crush and Tesla 3Q — 5 things to know today

    By Laura Lorenzetti and Geoffrey Smith
  • Apple Watch fitness milanese loop bandTech

    IBM’s Watson makes its health care debut on the Apple Watch

    By
  • A high price for a groundbreaking treatment.Retail

    Why the drug price scandal won’t be enough to keep down prices

    By
  • Imprimis Turing DrugHealth

    This company is offering a $1 alternative to Turing’s $750 drug

    By
  • 2012 Jackie Robinson Foundation Awards DinnerFinance

    Why this CEO is missing out on an $80 million payday

    By
  • Tech

    Former DEA agent gets prison time for stealing bitcoins

    By
  • Unboxing Apple Inc. iPhone 6sTech

    Instagram has an answer to the iPhone’s coolest feature

    By
  • J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)Finance

    Forget the plunging stock price, here’s Valeant’s biggest problem

    By
  • Kate Moss Modelling Contracts At RiskLuxury

    Here’s how Burberry is taking to Snapchat again

    By
  • Microsoft unveiled its first-ever laptop, the Surface Book, earlier this month.Tech

    Microsoft finally has a laptop to compete with Apple

    By
  • AB InBev And SABMiller Beers On Display Following $106 Billion DealRetail

    Drink Beck’s? You can expect some checks

    By
  • J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)Health

    Short-seller: Is Valeant the pharmaceutical Enron?

    By